What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Breast cancer
Her main research concerns Breast cancer, Internal medicine, Oncology, Surgery and Radiation therapy.
Her Breast cancer research also works with subjects such as
- Disease that connect with fields like Concomitant,
- Learned helplessness that intertwine with fields like Cohort study.
Internal medicine connects with themes related to Gynecology in her study.
In her research on the topic of Oncology, Whole Breast Irradiation, Bisphosphonate, Adjuvant therapy, Zoledronic acid and Menopause is strongly related with Metastasis.
The study incorporates disciplines such as Pituitary adenoma and Hazard ratio in addition to Surgery.
Her research integrates issues of Regimen, Mastectomy and Adverse effect in her study of Radiation therapy.
Her most cited work include:
- A Randomized Trial Of Exemestane After Two To Three Years Of Tamoxifen Therapy In Postmenopausal Women With Primary Breast Cancer. (1568 citations)
- A pooled analysis of bone marrow micrometastasis in breast cancer (1067 citations)
- The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. (895 citations)
What are the main themes of her work throughout her whole career to date?
Judith M. Bliss spends much of her time researching Internal medicine, Oncology, Breast cancer, Cancer and Surgery.
Internal medicine is closely attributed to Gynecology in her work.
Her Oncology research is multidisciplinary, relying on both Aromatase inhibitor, Epirubicin, Fulvestrant and Early breast cancer.
Her studies in Breast cancer integrate themes in fields like Clinical endpoint, Clinical trial, Randomized controlled trial, Pathology and Hazard ratio.
Her Cancer study combines topics in areas such as Biomarker and Cohort.
Judith M. Bliss studies Surgery, namely Regimen.
She most often published in these fields:
- Internal medicine (62.60%)
- Oncology (53.25%)
- Breast cancer (47.01%)
What were the highlights of her more recent work (between 2015-2021)?
- Internal medicine (62.60%)
- Oncology (53.25%)
- Breast cancer (47.01%)
In recent papers she was focusing on the following fields of study:
Her primary areas of study are Internal medicine, Oncology, Breast cancer, Radiation therapy and Cancer.
Her research in Oncology intersects with topics in Fulvestrant, Palbociclib, Cohort and Early breast cancer.
She combines subjects such as Clinical endpoint, Clinical trial, Chemotherapy, Adverse effect and Hazard ratio with her study of Breast cancer.
Her study in Hazard ratio is interdisciplinary in nature, drawing from both Mastectomy and Proportional hazards model.
Radiation therapy is a subfield of Surgery that Judith M. Bliss studies.
Her Cancer research includes themes of Disease and Intensive care medicine.
Between 2015 and 2021, her most popular works were:
- Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer (357 citations)
- Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (293 citations)
- Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: The TNT Trial (282 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Breast cancer
Judith M. Bliss focuses on Internal medicine, Breast cancer, Oncology, Radiation therapy and Randomized controlled trial.
Many of her studies on Internal medicine apply to Alveolar soft part sarcoma as well.
Breast cancer is a subfield of Cancer that Judith M. Bliss explores.
The study incorporates disciplines such as Aromatase inhibitor, Early breast cancer, Palbociclib, Estrogen receptor and Exemestane in addition to Oncology.
The concepts of her Radiation therapy study are interwoven with issues in Regimen, Physical therapy, Adjuvant and Adverse effect.
Her studies in Randomized controlled trial integrate themes in fields like Letrozole and Radiology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
